Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.
$IKNA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Ikena Oncology, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
45175G108
(CUSIP Number)
September 30, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
☐
|
Rule 13d-1(b)
|
|
|
☒
|
Rule 13d-1(c)
|
|
|
☐
|
Rule 13d-1(d)
|
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”), or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)
SCHEDULE 13G
CUSIP No. 45175G108
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
|
BRISTOL-MYERS SQUIBB COMPANY
22-0790350
|
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Delaware, U.S.A.
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
-0-
|
|
|
|||
|
|
|
||||
|
6
|
SHARED VOTING POWER
|
|
|
||
|
2,133,142(1)
|
|
|
|||
|
|
|
||||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
-0-
|
|
|
|||
|
|
|
||||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
2,133,142(1)
|
|
|
|||
|
|
|
||||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
2,133,142(1)
|
|
|
|||
|
|
|
||||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
|
4.4%(2)
|
|
|
|||
|
|
|
||||
|
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
|
CO
|
|
|
|||
|
|
|
||||
|
(1)
|
See Item 4 below.
|
|
(2)
|
The percentage ownership interest is determined based on 48,258,111 shares of Common Stock outstanding as of November 1, 2024, as reported on the Issuer’s Form 10-Q, filed on November
7, 2024.
|
CUSIP No. 45175G108
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
|
CELGENE CORPORATION
22-2711928
|
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Delaware, U.S.A.
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
-0-
|
|
|
|||
|
|
|
||||
|
6
|
SHARED VOTING POWER
|
|
|
||
|
2,133,142(1)
|
|
|
|||
|
|
|
||||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
-0-
|
|
|
|||
|
|
|
||||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
2,133,142(1)
|
|
|
|||
|
|
|
||||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
2,133,142(1)
|
|
|
|||
|
|
|
||||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
|
4.4%(2)
|
|
|
|||
|
|
|
||||
|
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
|
CO
|
|
|
|||
|
|
|
||||
|
(1)
|
See Item 4 below.
|
|
|
(2)
|
The percentage ownership interest is determined based on 48,258,111 shares of Common Stock outstanding as of November 1, 2024, as reported on the Issuer’s Form 10-Q, filed on November 7,
2024.
|
| Item 1 (a). |
Name of Issuer:
|
Ikena Oncology, Inc.
| Item 1(b). |
Address of Issuer’s Principal Executive Offices:
|
645 Summer Street
Suite 101
Boston, MA 02210
| Item 2(a). |
Name of Persons Filing:
|
This statement on Schedule 13G is being jointly filed by: (i) Bristol-Myers Squibb Company (“BMS”) and (ii) Celgene Corporation (“Celgene”). Celgene is a direct wholly owned subsidiary of BMS.
| Item 2(b). |
Address of Principal Business Office or, if None, Residence:
|
|
BMS
|
Celgene
|
|
|
Route 206 & Province Line Road
|
Route 206 & Province Line Road
|
|
|
Princeton, New Jersey 08543
|
Princeton, New Jersey 08543
|
| Item 2(c). |
Citizenship:
|
Delaware, U.S.A.
| Item 2(d). |
Title of Class of Securities:
|
Common Stock, $0.001 par value
| Item 2(e). |
CUSIP Number:
|
45175G 108
| Item 3. |
If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
☐
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
|
(b)
|
☐
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
|
(c)
|
☐ |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
|
(d)
|
☐ |
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
|
|
(e)
|
☐ |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
(f)
|
☐ |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
(g)
|
☐ |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
(h)
|
☐
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
(i)
|
☐ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
|
|
|
(j)
|
☐ |
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
|
|
|
(k)
|
☐ |
Group, in accordance with § 240.13d–1(b)(1)(ii)(K).
|
Not applicable.
| Item 4. |
Ownership.
|
|
(a)
|
Amount beneficially owned:
|
|
|
2,133,142 shares of Common Stock of the Issuer*
|
|
(b)
|
Percent of class: 4.4%**
|
||
|
(c)
|
Number of shares as to which such person has:
|
||
|
(i)
|
Sole power to vote or to direct the vote:
|
||
| 0 | |||
|
(ii)
|
Shared power to vote or to direct the vote:
|
|
|
2,133,142 shares of Common Stock of the Issuer*
|
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
|
|
0
|
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
|
|
2,133,142 shares of Common Stock of the Issuer*
|
* Celgene, a direct wholly owned subsidiary of BMS, is the record holder of 2,133,142 shares of Common Stock of the Issuer. BMS does not directly own any shares of Common Stock of the Issuer. By reason of the
provisions of Rule 13d-3 under the Act, BMS is deemed to own beneficially the Common Stock that Celgene owns as a record holder.
** The percentage ownership interest is determined based on 48,258,111 shares of Common Stock outstanding as of November 1, 2024, as reported on the Issuer’s Form 10-Q, filed on November 7, 2024.
| Item 5. |
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check
the following ☒
| Item 6. |
Ownership of More Than Five Percent on Behalf of Another Person.
|
Not applicable.
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
|
Not applicable.
| Item 8. |
Identification and Classification of Members of the Group.
|
Not applicable.
| Item 9. |
Notice of Dissolution of Group.
|
Not applicable.
| Item 10. |
Certifications.
|
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination
under §240.14a-11.
|
Exhibit Description
|
|
|
99.1
|
Joint Filing Agreement, dated April 5, 2021, between BMS and Celgene.
|
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
|
Date: November 13, 2024
|
|||
|
BRISTOL-MYERS SQUIBB COMPANY
/s/ Amy Fallone
|
|||
|
Name:
|
Amy Fallone
|
||
|
Title:
|
Corporate Secretary
|
||
|
CELGENE CORPORATION
/s/ Amy Fallone
|
|||
|
Name:
|
Amy Fallone
|
||
|
Title:
|
Vice President and Secretary
|
||